Plain-English translation of NCT07085169 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications—trifluridine/tipiracil and bevacizumab—at lower doses than usual to treat colorectal cancer that has spread to other parts of the body or stopped responding to earlier treatments. The goal is to find out if using lower doses can be just as effective while causing fewer side effects. You would receive the medication in repeating two-week cycles until your cancer stops responding or the side effects become too much to tolerate.
Standard doses of trifluridine/tipiracil can cause serious side effects that make it hard for patients to continue treatment. Researchers want to see if lower doses of this medication, combined with bevacizumab, can still fight cancer effectively while being easier on your body.
You likely qualify if…
You likely don't qualify if…
You would take oral medication (a pill) twice daily for 10 days, followed by 4 days of rest—this repeats every two weeks. On day 1 of each cycle, you would also receive an intravenous infusion (through an IV) of the second medication at the hospital. You would continue this routine until your cancer progresses, the side effects become too difficult to manage, or you choose to stop. Your doctor will monitor you closely with blood tests and scans to see how the treatment is working.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China